바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.62 No.2
Citation Share

Acute Respiratory Failure Developed in Non-small Cell Lung Cancer Patients Treated With Gefitinib

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2007, v.62 no.2, pp.144-148







& (2007). Acute Respiratory Failure Developed in Non-small Cell Lung Cancer Patients Treated With Gefitinib. Tuberculosis & Respiratory Diseases, 62(2), 144-148.
  • Downloaded
  • Viewed
PDF Download

Abstract

Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. We describe two non-small cell lung cancer patients who developed acute respiratory failure after gefitinib, and suggest that clinicians take extreme caution when deciding to treat patients with gefitinib. (Tuberc Respir Dis 2007; 62: 144-148)

keywords
Adverse effect, Gefitinib, Lung cancer.

Reference

1.

(2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib,

2.

(2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets,

3.

(2004) Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib,

4.

(2003) Severe acute interstitial pneumonia and gefitinib,

5.

(2006) Gefitinib-induced lung injury successfully treated with high-dose corticosteroids,

6.

(2004) Acute gefitinib-induced pneumonitis,

7.

(2003) Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine,

8.

(2003) Acute lung injury as a possible adverse drug reaction related to gefitinib,

9.

(2003) Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer,

10.

(2004) Acute lung injury as an adverse event of gefitinib,

11.

(2005) Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis,

12.

(2004) Severe acute interstitial pneumonia and gefitinib,

13.

(2003) Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis,

14.

(2006) Gefitinib prevents bleomycin-induced lung fibrosis in mice,

15.

(2006) Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy